A Phase 3 interventional study of Placebo and Rituximab in Indolent Non-Hodgkin's Lymphomas, sponsored by Gilead Sciences. Terminated at 103 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.
Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 27th largest by enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2013, is one of 35 in phase 3, and was the 143rd registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 129 · Phase 3 37
First in 1997; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 295 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 188 interventional studies. Of the 150 that completed or were terminated, 75 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 194 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
17 studies in Lymphoma, Follicular by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 9 (69%) have results posted.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2013, is one of 5 in phase 3, and was the 8th registered.
Gilead Sciences’s Lymphoma, Follicular studies by the year they started, since 1997.
5 of the studies testing rituximab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT01473628M.D. Anderson Cancer CenterRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | 2027-05-20 |
| NCT04998669Juan P. Alderuccio, MDLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 194 studies testing rituximab in Lymphoma, Follicular, from their registry updates:
Among Gilead Sciences’s 17 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Key Inclusion Criteria:
confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab + idelalisib.
Drug: Rituximab · Drug: Idelalisib
Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
Drug: Placebo · Drug: Rituximab · Drug: Idelalisib
Tablets administered orally twice daily
375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
Also known as: Rituxan®, MabThera®
150 mg tablets administered orally twice daily
Also known as: GS-1101, CAL-101, Zydelig®
Progression Free Survival
Progression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC).
Overall Response Rate
Overall Response Rate (ORR) is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response or minor response for participants with Waldenstrom's). ORR was to be assessed by an IRC.
Lymph Node Response Rate
Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.
Complete Response Rate
Complete response rate is defined as the proportion of participants who achieve a complete response. Complete response rate was to be assessed by an IRC.
Overall Survival
Overall survival is defined as the interval from randomization to death from any cause.
Participants were enrolled at study sites in the North America, Europe, and Asia Pacific. The first participant was screened on 16 January 2013. The last study visit occurred on 18 May 2016.
| Milestone | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| Started | 198 | 97 |
| Completed | 42 | 28 |
| Not completed | 156 | 69 |
| Withdrew: Study terminated by sponsor | 105 | 55 |
| Withdrew: Withdrawal by subject | 27 | 4 |
| Withdrew: Physician decision | 14 | 7 |
| Withdrew: Other | 7 | 1 |
| Withdrew: Initiation of other anti-cancer therapy | 3 | 2 |
Progression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC).
No measurements were reported for this outcome.
Overall Response Rate (ORR) is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response or minor response for participants with Waldenstrom's). ORR was to be assessed by an IRC.
No measurements were reported for this outcome.
Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Complete response rate is defined as the proportion of participants who achieve a complete response. Complete response rate was to be assessed by an IRC.
No measurements were reported for this outcome.
Overall survival is defined as the interval from randomization to death from any cause.
No measurements were reported for this outcome.
Collected over Up to 27 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib + Rituximab | — | 103/198 (52%) | 189/198 (95.5%) |
| Placebo + Rituximab | — | 11/95 (11.6%) | 83/95 (87.4%) |
| Event | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| PneumoniaInfections and infestations | 19/198 | 0/95 |
| DiarrhoeaGastrointestinal disorders | 18/198 | 0/95 |
| Alanine aminotransferase increasedInvestigations | 11/198 | 0/95 |
| Aspartate aminotransferase increasedInvestigations | 10/198 | 0/95 |
| PyrexiaGeneral disorders | 9/198 | 1/95 |
| ColitisGastrointestinal disorders | 8/198 | 0/95 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 8/198 | 0/95 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/198 | 0/95 |
| SepsisInfections and infestations | 5/198 | 0/95 |
| Acute kidney injuryRenal and urinary disorders | 5/198 | 0/95 |
| Event | Idelalisib + Rituximab | Placebo + Rituximab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 88/198 | 18/95 |
| Alanine aminotransferase increasedInvestigations | 65/198 | 0/95 |
| Aspartate aminotransferase increasedInvestigations | 56/198 | 0/95 |
| NauseaGastrointestinal disorders | 50/198 | 12/95 |
| PyrexiaGeneral disorders | 50/198 | 11/95 |
| FatigueGeneral disorders | 41/198 | 20/95 |
| Infusion related reactionInjury, poisoning and procedural complications | 36/198 | 20/95 |
| RashSkin and subcutaneous tissue disorders | 38/198 | 12/95 |
| HeadacheNervous system disorders | 30/198 | 12/95 |
| CoughRespiratory, thoracic and mediastinal disorders | 28/198 | 14/95 |
Intent-to-Treat (ITT) Analysis Set: all participants who were randomized regardless of whether they received any study treatment
| Age, Continuous(years) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Mean | 64 ± 11.4 | 67 ± 11.4 | 65 ± 11.4 |
| Sex: Female, Male(Participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Female | 99 | 48 | 147 |
| Male | 99 | 49 | 148 |
| Race/Ethnicity, Customized(Participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Asian | 35 | 17 | 52 |
| Black or African American | 5 | 4 | 9 |
| White | 123 | 54 | 177 |
| Other | 3 | 3 | 6 |
| Not Permitted | 32 | 19 | 51 |
| Race/Ethnicity, Customized(Participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 3 | 15 |
| Not Hispanic or Latino | 150 | 75 | 225 |
| Unknown or Not Reported | 36 | 19 | 55 |
| Region of Enrollment(Participants) | Idelalisib + Rituximab | Placebo + Rituximab | Total |
|---|---|---|---|
| Russian Federation | 7 | 2 | 9 |
| Singapore | 5 | 4 | 9 |
| Romania | 1 | 0 | 1 |
| Hungary | 24 | 6 | 30 |
| United States | 65 | 34 | 99 |
| Japan | 23 | 9 | 32 |
| United Kingdom | 3 | 1 | 4 |
| Portugal | 3 | 1 | 4 |
| Spain | 6 | 0 | 6 |
| Czech Republic | 2 | 0 | 2 |
| Sweden | 6 | 2 | 8 |
| Taiwan | 1 | 1 | 2 |
| Poland | 5 | 7 | 12 |
| Korea, Republic of | 4 | 2 | 6 |
| Italy | 7 | 4 | 11 |
| Israel | 3 | 0 | 3 |
| Australia | 7 | 6 | 13 |
| France | 25 | 17 | 42 |
| Germany | 1 | 1 | 2 |
Showing the first 100 of 103 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Jan 2013 to primary completion in May 2016, 40 months.
Results were first posted in May 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Idelalisib